A phase II, open-label, multi-centre study to evaluate safety, tolerability, efficacy, pk, and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with advanced solid tumours expressing claudin 18.2.

MyChart

Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
Request an Appointment

If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information

New Patients Current Patients Referring Physicians
Donate Today